L-histidinol increases the vulnerability of cultured human leukemia and lymphoma cells to anticancer drugs.
L-Histidinol, a structural analogue of the essential amino acid L-histidine, enhances the toxicity of a variety of anticancer drugs for many tumor cells of animal origin. In this study, the effects of L-histidinol on the proliferation and anticancer drug susceptibility of two human tumor cell lines of lymphoid origin, Daudi and MOLT 4, have been examined. L-Histidinol increased the inherent capacity of six different antineoplastic agents to kill these human tumor cells, in a dose- and time-dependent manner, in spite of the observation that it slowed cell cycle progression in both lines.
Warrington
R C
RC
Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada.
Cheng
I
I
Zhang
L
L
Fang
W D
WD
D000970:Antineoplastic Agents / Q000633:toxicity*; D002330:Carmustine / Q000633:toxicity; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D002945:Cisplatin / Q000633:toxicity; D003630:Daunorubicin / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005472:Fluorouracil / Q000633:toxicity; D006641:Histidinol / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D007938:Leukemia; D008223:Lymphoma; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D006641:Histidinol; D002945:Cisplatin; D005472:Fluorouracil; D002330:Carmustine; D003630:Daunorubicin